Tukysa (tucatinib) + Herceptin (trastuzumab) Emerging Drug Insight and Market Forecast - 2032

“Tukysa (tucatinib) ± Herceptin (trastuzumab) Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Tucatinib ± Trastuzumab market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Tukysa (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth. HER2 is overexpressed in multiple cancers, including colorectal cancer. In preclinical in vitro studies, the drug inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. The combination of Tukysa and trastuzumab have also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Trastuzumab is a type of targeted cancer drug called a monoclonal antibody. It works by attaching to HER2, so it stops the cancer cells from growing and dividing.

Tukysa, in combination with trastuzumab and capecitabine was approved by the US FDA in April 2020 for adult patients with advanced, unresectable, or metastatic HER2-positive breast cancer, including patients with brain metastases.

Currently, Seagen is conducting a phase II trial, called MOUNTAINEER, evaluating tucatinib alone or in combination with trastuzumab for the treatment of 2L+ HER2-positive RAS wild-type metastatic colorectal cancer.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Tucatinib ± Trastuzumab description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Tucatinib ± Trastuzumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Tucatinib ± Trastuzumab research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Tucatinib ± Trastuzumab.
• The report contains forecasted sales of Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tucatinib ± Trastuzumab Analytical Perspective

In-depth Tucatinib ± Trastuzumab Market Assessment

This report provides a detailed market assessment of Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Tucatinib ± Trastuzumab Clinical Assessment

The report provides the clinical trials information of Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tucatinib ± Trastuzumab dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Tucatinib ± Trastuzumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer.
• This in-depth analysis of the forecasted sales data of Tucatinib ± Trastuzumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Tucatinib ± Trastuzumab?
• What is the clinical trial status of the study related to Tucatinib ± Trastuzumab in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tucatinib ± Trastuzumab development?
• What are the key designations that have been granted to Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Tucatinib ± Trastuzumab for s?
• What are the forecasted sales of Tucatinib ± Trastuzumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Tucatinib ± Trastuzumab for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?

This product will be delivered within 2 business days.